Chinook Therapeutics, Inc.
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Aduro Biotech, Inc. (to 2020)
0
Ending by 2030
Jan 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 17, 2027The maintenance fee for Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use (US 10,414,789) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 23, 2026
- Sep 23 US 8,840,881 Methods and Compositions for Treating Prostate Cancer or Inducing a Humoral Immune Response Against Prostate Cancer · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,414,789 | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use In force · USPTO record | In force | USPTO record | |
| US 9,695,212 | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use In force · USPTO record | In force | USPTO record | |
| US 10,738,056 | Pyrazolopyrimidinone compounds and uses thereof In force · USPTO record | In force | USPTO record | |
| US 11,491,137 | Methods of Improving Renal Function In force · Medium confidence | In force | Medium confidence | |
| US 11,998,526 | Methods of Improving Renal Function In force · Medium confidence | In force | Medium confidence | |
| US 12,121,509 | Methods of Improving Renal Function In force · Low confidence | In force | Low confidence | |
| US 12,370,174 | Methods of Improving Renal Function In force · Low confidence | In force | Low confidence | |
| US 12,521,369 | Methods of Improving Renal Function In force · Medium confidence | In force | Medium confidence | |
| US 12,582,631 | Methods of Improving Renal Function In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 9: 7 patents in force now held by others · 11 lapsed for an unpaid fee · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 5 abandoned · 1 no status recorded